<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728286</url>
  </required_header>
  <id_info>
    <org_study_id>3639b</org_study_id>
    <secondary_id>British Heart Foundation</secondary_id>
    <nct_id>NCT00728286</nct_id>
  </id_info>
  <brief_title>Assessment of Thrombogenicity in Acute Coronary Syndrome</brief_title>
  <official_title>Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Newcastle Upon-Tyne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Newcastle-upon-Tyne Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess platelet dependent thrombogenicity in patients after
      acute coronary syndrome using an ex vivo arterial injury model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abnormal platelet activity seen in patients with Type2 Diabetes Mellitus (T2DM) may be an
      important contributor to their enhanced cardiovascular risk and higher rates of
      cardiovascular events following acute coronary syndrome, despite dual antiplatelet therapy
      with aspirin and clopidogrel. We have earlier demonstrated high thrombogenicity in
      individuals with T2DM and CAD in the absence of acute ischaemic events, despite therapeutic
      doses of aspirin.We hypothesise that patients with T2DM will have increased thrombogenicity
      after acute coronary syndrome despite optimal secondary prevention medication.Measuring ex
      vivo thrombus area using an arterial injury model simulates plaque rupture and reflects the
      summative effect of all haemostatic abnormalities. The thrombus area of patients with ACS and
      T2DM will be compared to the controls without T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombus area</measure>
    <time_frame>Within 10 days after acute coronary syndrome</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors affecting thrombus area</measure>
    <time_frame>Within ten days after acute coronary syndrome</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes mellitus</arm_group_label>
    <description>We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-ST elevation myocardial infarction - Acute Coronary syndrome (ACS) and on
        existing medication will undergo chamber study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute coronary syndrome (WHO criteria) with raised cardiac troponin T

          -  Aged 18-80 years

          -  Stable Acute coronary syndrome

          -  On aspirin and clopidogrel

          -  Willing to participate in the study

        Exclusion Criteria:

          -  Smoking (current smokers or smokers who quit in the last 6 months preceding
             recruitment)

          -  Malignancy (any suspected or proven)

          -  Haematological disorders (bleeding disorders)

          -  Pre-menopausal women

          -  Use of corticosteroids/other antithrombotic agents (warfarin)

          -  Chronic liver disease

          -  Unable to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azfar G Zaman, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Freeman Hospital, Newcastle upon Tyne NHS Trust, Newcastle upon Tyne. NE7 7DN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Victoria Hospital, Newcastle upon Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Natarajan A, Marshall S, Worthley S, Badimon J, Zaman A.Platelet-dependent thrombosis in patients with type 2 diabetes and coronary artery disease - vulnerable blood and efficacy of aspirin. Journal of Thrombosis and Heamostasis(under review)</citation>
  </reference>
  <reference>
    <citation>Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, Heflt G, Fallon JT, Crandall JP. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001 Nov 1;38(5):1307-12.</citation>
    <PMID>11691500</PMID>
  </reference>
  <reference>
    <citation>Shechter M, Merz CN, Paul-Labrador MJ, Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol. 2000 Feb;35(2):300-7.</citation>
    <PMID>10676673</PMID>
  </reference>
  <reference>
    <citation>Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI, Farkouh ME, Fuster V, Badimon JJ, Chesebro JH. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2316-21.</citation>
    <PMID>11031221</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Platelet dependent thrombogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

